Here, we report that aberrant promoter methylation of DAPK1, RIZ1, P16INK4A, RASSF1A and p14ARFARF genes is significantly associated with; CML disease progression to advanced clinical stages, poor imatinib response and poor overall survivals as well. The gene discussed is CDKN2A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.